The most common nonfamilial forms of amyloidosis that involve the kidney are the AL (amyloid light chain) and AA (serum amyloid A) types. These two forms require different treatment strategies ...

Almost four years after it was approved in Europe to treat the incurable rare disease systemic amyloid light-chain (AL) amyloidosis, Johnson & Johnson’s Darzalex has been given the go-ahead for ...

AL (immunoglobulin light chain) amyloidosis is a rare disease that often results in progressive organ dysfunction, organ failure and eventual death. Clonal plasma cells in the bone marrow secrete ...

The deal gives the Anglo-Swedish drugmaker complete control of Caelum's late-stage medicine for light chain (AL) amyloidosis, a potentially fatal disease that causes the rogue protein amyloid to ...

Successfully dosed 6 patients in safety run-in segment, now accelerating enrollment Positive data from first four patients announced December 2024 NXC-201 is the only one-time CAR-T therapy in ...

AL Amyloidosis is a life-threatening disorder of plasma cells in the bone marrow affecting ~33,000 patients in the U.S. LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc.

Detailed price information for Immix Biopharma Inc (IMMX-Q) from The Globe and Mail including charting and trades.

Oppenheimer raised the firm’s price target on Prothena (PRTA) to $62 from $58 and keeps an Outperform rating on the shares. The firm sees a ...

[Ash 2020;5b] Amyloidoses which can affect the heart include: Amyloid light-chain (AL) amyloidosis (also known as primary amyloidosis), caused by aggregation of monoclonal kappa or lambda light ...

Closing in on 25 years since the World Trade Center (WTC) attacks, WTC responders continue to suffer long-term effects from their exposures at Ground Zero. One issue of possible growing concern is ...